Moody Neurorehabilitation Institute Acquires Wandercraft’s Atalante X to Transform Care for Complex Patients
New York, NY (July 9, 2025) — Wandercraft, the global leader in self-balancing robotic exoskeletons, today announced the deployment of the Atalante X exoskeleton to Moody Neurorehabilitation Institute (Moody Neuro), a nationally recognized leader in post-acute brain injury rehabilitation. The addition marks a significant step forward in Moody Neuro’s ability to provide high-intensity, hands-free gait therapy to patients with complex mobility challenges.
Moody Neuro selected the Atalante X after a rigorous evaluation process that included extensive clinical and technical review, hands-on demonstrations, and feedback from a board of medical experts and rehabilitation and academic specialists.
“After a thorough review, our clinical and leadership teams agreed that the Atalante X stands out as the best-in-class rehabilitation exoskeleton,” said Jeff Eppinette, MBA, President and CEO of Moody Neurorehabilitation Institute. “Its advanced capabilities, combined with the exceptional technical and clinical support from Wandercraft, made this a clear choice for our program. We are sure that this will enhance outcomes for many of our patients recovering from traumatic brain injuries.”
The Atalante X is a fully self-balancing, hands-free exoskeleton that helps patients walk, stand, and retrain natural movement patterns from their very first session. Unlike other robotic rehabilitation devices, the Atalante X does not depend on patients using assistive devices such as walkers or crutches. This makes the Atalante X especially useful for individuals with complex conditions or limited upper-body strength.
“We’re excited to see the powerful benefits of incorporating Atalante X into our treatment plans,” said Lori Stacks, PT, DPT, Chief Clinical Officer of Moody Neurorehabilitation Institute. “What sets this device apart is its hands-free mobility and its ability to accommodate even our most complex patients. These include individuals with traumatic brain injuries (TBI) with resulting disorders of consciousness (DoC), which are severe impairments of awareness and wakefulness. Atalante X could open up new opportunities for engagement, motivation, and functional progress during our patients’ rehab journey.”
This milestone further affirms a growing shift in neurorehabilitation: toward technologies that prioritize natural movement, intensive therapy, and patient-centered outcomes. By equipping clinicians with tools like Atalante X, institutions like Moody Neuro are not only improving care—they’re redefining what recovery can look like. Wandercraft and Moody Neuro share a common vision: restoring upright independence and possibility to individuals facing some of life’s most difficult challenges.
“We deeply value the confidence Moody Neuro has placed in us and are thrilled to collaborate with their exceptional clinical team,” said Matthieu Masselin, CEO and co-founder of Wandercraft. “Atalante X was designed to help people stand, walk, and restore upright mobility– and it’s inspiring to see leading institutions like Moody embrace this technology to reshape neurorehabilitation.”
The Atalante X is currently used in more than 100 research and rehabilitation centers worldwide. So far, it has received U.S. Food and Drug Administration (FDA) clearance for patients with spinal cord injuries (T5–L5) and post-stroke rehabilitation, and it holds CE Mark certification in Europe. The company recently announced its next major milestone – the clinical trials for Eve, a personal exoskeleton developed for everyday use, which brings the same self-balancing technology into homes and communities.
About Wandercraft
Wandercraft is a global robotics company on a mission to restore mobility and expand what’s possible through self-balancing, AI-powered systems. Known for its groundbreaking Personal Exoskeleton, Eve, Wandercraft is developing the next generation of mobility solutions to restore walking ability both at home and in rehabilitation. Its flagship device, the Atalante X, is a groundbreaking self-balancing exoskeleton used at more than 100 inpatient and outpatient rehabilitation centers.
In 2025, Wandercraft expanded into industrial robotics with the launch of Calvin-40, a strong, voice-controlled humanoid robot developed through a strategic partnership with Renault Group. Built on the same life-tested robotics platform as Wandercraft’s medical exoskeletons, Calvin is engineered to perform physically demanding or hazardous tasks in real-world environments, starting with automotive manufacturing. With more than 30 patents and a deeply human mission, Wandercraft believes that everyone should have the chance to move freely – and that robotics should connect with people where they are, with reliability, responsiveness, and purpose. Learn more at wandercraft.eu.
About Moody Neurorehabilitation Institute
Moody Neurorehabilitation Institute is a leading provider of post-acute neurorehabilitation services, dedicated to helping brain injury survivors reintegrate into their communities and maximize their quality of life. Founded in 1982, Moody Neuro has grown into a nationally recognized center of excellence with locations in Galveston, Houston, and Lubbock, Texas.
With an unwavering belief that each patient is unique, Moody Neuro provides highly specialized, personalized care through expert clinical and direct care staff, state-of-the-art facilities and therapy equipment, and a culture of clinical innovation. The Moody Neuro staff consists of some of the most passionate and experienced clinicians, caregivers and administrative staff in the field, united by a shared mission to improve lives and set the standard for neurocognitive rehabilitation. For more information, visit www.moodyneuro.org.
Media Contacts
Lilly Kofler
Global Head of Marketing & Communications
lilly.kofler@wandercraft.health
Courtney Gifford
Business Development Coordinator
cgifford@moodyneuro.org
